Microbix Biosystems Inc T.MBX

Alternate Symbol(s): MBXBF

Healthcare Biotechnology

Microbix Biosystems Inc. develops and commercializes biological and technological solutions for human health and wellbeing. It enables the commercialization of diagnostic assays by making a range of critical ingredients and devices for the global diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment products (QAPs) that support clinical lab proficiency testing, enable assay development and validation, or help ensure the quality of clinical diagnostic workflows. Its segments include development, manufacturing and sales of products relating to the medical diagnostics industry, namely antigens as test ingredients, quality assessment products to help ensure the accuracy of test workflows and viral transport medium to enable collection of patient test samples and, and development and commercialization of novel and proprietary products or technologies, such as Kinlytic. Its Kinlytic urokinase is a biologic thrombolytic drug used to treat blood clots.

TSX:MBX - Post by User

Microbix Biosystems Inc > Stats

<< Previous

Bullboard Posts

Next >>

Comment by lscfaon Feb 09, 2023 4:45pm

140 Views

Post# 35278235

RE:Stats

More stats.....

Qtr ending	Antigen	QAP	DxTM	Royalties	Total Revenue
Dec 22	1,003,807	1,333,503	0	164,762	2,502,072
Sept 22	2,629,901	1,601,900	0	97,300	4,329,101
Jun 22	2,283,621	1,305,896	1,326,410	95,099	5,011,026
Mar 22	1,607,970	1,318,382	1,860,704	93,508	4,880,564
Dec 21	1,766,416	1,149,151	1,817,245	122,787	4,855,599
Sep 21	2,020,861	1,195,545	2,327,600	85,689	5,629,695
Jun 21	2,398,969	1,051,617	1,924,300	76,948	5,451,834
Mar 21	2,524,363	1,495,088	255,000	79,322	4,353,773
Dec 20	2,137,829	962,421	0	57,409	3,157,659